FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2488978306> ?p ?o ?g. }

• W2488978306 abstract "Abstract Chronic lymphocytic leukemia (CLL) is characterized by the accumulation in the peripheral blood, secondary lymphoid tissues and bone marrow of functionally defective clonal B lymphocytes with prolonged survival in vivo. Despite therapeutic achievements have been accomplished in the management of this disease, however CLL remains incurable partially because of the resistance to apoptosis of CLL B-cells and of the altered immune system of CLL patients. CLL is hetereogenous, but its evolution is mostly slow, probably linked to some level of immune control of the leukemic cells. Indeed, clinical observations have been reported of spontaneous remissions associated with the intense immunological activity following a viral infection. Clinical responses have also been observed after treatment by immunomodulating cytokines and long-term survival is described, without disease, after allogeneic stem cells transplantation. All these data suggest that immunotherapy could be useful in the treatment of CLL, possibly as an adjuvant therapy after classical immunochemotherapy schedules. Toll like receptors (TLR) are proteins of the innate immune system belonging to the family of Pattern Recognition receptors (PRRs). Recognition of their ligands by the TLR present on neutrophils, macrophages, dendritic cells and B-cells are important in the initiation of adaptive immune responses. TLR-7 and 9 are expressed by CLL B-cells (Grandjenette, Hematologica, 2007). Previous studies have shown that stimulation of TLR-9 by CpG ODN (oligodinucleotides) induces an activation of CLL B-cells while triggering TLR-7 increases in vitro apoptosis of these cells. Here we show that these effects of TLR-9 and TLR-7 stimulation differ depending on the clinical form (stable or aggressive) of the disease and on the mutational status of CLL B-cells. In vitro stimulation with three doses of Imiquimod R837 or ODN CpG M362 was carried out for three days on cells from 40 patients (22 stable, 18 aggressive, mutational status known for 35, 18 IgVH mutated, 17 unmutated). Flow cytometry was used to measure apoptosis, proliferation after carboxyfluorescein succinimidyl ester (CFSE) labeling and modulation of surface differentiation antigens. Signaling pathways after incubation were further studied by antibody arrays and western blot. Spontaneous apoptosis occurring in vitro was demonstrated to involve the mitochondrial pathway. CLL B-cells were also confirmed to proliferate strongly and produce large amounts of IL-6 and IL-8 upon triggering by phorbol myrsistate (positive control), this compound almost completely aborting in vitro apoptosis. Cells from patients with a stable disease were significantly more prone to rapid apoptosis after TLR-7 triggering with Imiquimod, compared to cells from patients with an aggressive disease which displayed only spontaneous apoptosis. This rapid apoptosis in stable patients involved the p38 MAP-Kinase pathway. It was concomitant to an important production of IL-8 and IL-6. Conversely, CpG ODN conferred a protection against apoptosis to CLL B-cells from patients with an aggressive disease. This was accompanied by the activation of numerous anti-apoptotic proteins in the cells. CpG ODN also significantly increased CLL B-cells proliferation, concomitantly to the phosphorylation of Erk and Akt proteins. ODN finally increased the expression of CD20 and CD19 on the cells’surface. The same differences in reactivity were observed comparing mutated (∼stable) and unmutated (∼aggressive) cases. These data indicate that CLL B-cells from patients with a stable or aggressive (mutated/unmutated) disease answer differently when triggered through their surface TLRs. This might have an incidence on the behavior of these cells in vivo, in answer to stimulations by microbial compounds naturally binding these structures. These properties could also be used to develop adjuvant immunotherapies by loading CpG ODN-activated CLL B-cells with autologous apoptotic fragments issued from stimulation of part of the same cells with Imiquimod. Disclosures: No relevant conflicts of interest to declare." @default.
• W2488978306 created "2016-08-23" @default.
• W2488978306 creator A5012718640 @default.
• W2488978306 creator A5015344865 @default.
• W2488978306 creator A5031034999 @default.
• W2488978306 creator A5065987951 @default.
• W2488978306 creator A5068303471 @default.
• W2488978306 creator A5072401370 @default.
• W2488978306 creator A5072852088 @default.
• W2488978306 date "2013-11-15" @default.
• W2488978306 modified "2023-09-26" @default.
• W2488978306 title "Differential Effects Of Triggering Via Toll Like Receptors In Stable Or Aggressive Chronic Lymphocytic Leukemia" @default.
• W2488978306 doi "https://doi.org/10.1182/blood.v122.21.5296.5296" @default.
• W2488978306 hasPublicationYear "2013" @default.
• W2488978306 type Work @default.
• W2488978306 sameAs 2488978306 @default.
• W2488978306 citedByCount "0" @default.
• W2488978306 crossrefType "journal-article" @default.
• W2488978306 hasAuthorship W2488978306A5012718640 @default.
• W2488978306 hasAuthorship W2488978306A5015344865 @default.
• W2488978306 hasAuthorship W2488978306A5031034999 @default.
• W2488978306 hasAuthorship W2488978306A5065987951 @default.
• W2488978306 hasAuthorship W2488978306A5068303471 @default.
• W2488978306 hasAuthorship W2488978306A5072401370 @default.
• W2488978306 hasAuthorship W2488978306A5072852088 @default.
• W2488978306 hasConcept C136449434 @default.
• W2488978306 hasConcept C170493617 @default.
• W2488978306 hasConcept C193419808 @default.
• W2488978306 hasConcept C203014093 @default.
• W2488978306 hasConcept C2776709828 @default.
• W2488978306 hasConcept C2777938653 @default.
• W2488978306 hasConcept C2778461978 @default.
• W2488978306 hasConcept C2780007613 @default.
• W2488978306 hasConcept C502942594 @default.
• W2488978306 hasConcept C55493867 @default.
• W2488978306 hasConcept C86803240 @default.
• W2488978306 hasConcept C8891405 @default.
• W2488978306 hasConceptScore W2488978306C136449434 @default.
• W2488978306 hasConceptScore W2488978306C170493617 @default.
• W2488978306 hasConceptScore W2488978306C193419808 @default.
• W2488978306 hasConceptScore W2488978306C203014093 @default.
• W2488978306 hasConceptScore W2488978306C2776709828 @default.
• W2488978306 hasConceptScore W2488978306C2777938653 @default.
• W2488978306 hasConceptScore W2488978306C2778461978 @default.
• W2488978306 hasConceptScore W2488978306C2780007613 @default.
• W2488978306 hasConceptScore W2488978306C502942594 @default.
• W2488978306 hasConceptScore W2488978306C55493867 @default.
• W2488978306 hasConceptScore W2488978306C86803240 @default.
• W2488978306 hasConceptScore W2488978306C8891405 @default.
• W2488978306 hasLocation W24889783061 @default.
• W2488978306 hasOpenAccess W2488978306 @default.
• W2488978306 hasPrimaryLocation W24889783061 @default.
• W2488978306 hasRelatedWork W1575391187 @default.
• W2488978306 hasRelatedWork W1823321223 @default.
• W2488978306 hasRelatedWork W1905034665 @default.
• W2488978306 hasRelatedWork W1967117798 @default.
• W2488978306 hasRelatedWork W1991384441 @default.
• W2488978306 hasRelatedWork W2006697405 @default.
• W2488978306 hasRelatedWork W2020029911 @default.
• W2488978306 hasRelatedWork W2047115666 @default.
• W2488978306 hasRelatedWork W2098126909 @default.
• W2488978306 hasRelatedWork W2117583924 @default.
• W2488978306 hasRelatedWork W2122878489 @default.
• W2488978306 hasRelatedWork W2201120979 @default.
• W2488978306 hasRelatedWork W2464630810 @default.
• W2488978306 hasRelatedWork W2569650666 @default.
• W2488978306 hasRelatedWork W2789465357 @default.
• W2488978306 hasRelatedWork W2895343571 @default.
• W2488978306 hasRelatedWork W2980126229 @default.
• W2488978306 hasRelatedWork W2980756705 @default.
• W2488978306 hasRelatedWork W2981020366 @default.
• W2488978306 hasRelatedWork W3131365538 @default.
• W2488978306 isParatext "false" @default.
• W2488978306 isRetracted "false" @default.
• W2488978306 magId "2488978306" @default.
• W2488978306 workType "article" @default.